Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Zentalis Pharmaceuticals received a consensus “Hold” rating from 10 analysts: five recommend buying, four advise holding, and one recommends selling. The average 12-month price target is $6.75.
• ZNTL shares opened at $2.52, well below the average analyst target, with a 52-week range of $1.21 to $6.95. The company has a market capitalization of approximately $180.6 million.
• The company reported a quarterly loss of $0.59 per share, missing the $0.49 consensus estimate, while major shareholder Group Walters purchased 4.335 million shares for approximately $15.2 million.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned a consensus rating of "Hold" from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $6.75.

ZNTL has been the topic of a number of analyst reports. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They set an "outperform" rating on the stock. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They issued an "equal weight" rating and a $5.00 price objective for the company. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an "outperform" rating and a $8.00 price objective for the company. Finally, Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a "buy" rating and a $11.00 target price on the stock.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $2.52 on Monday. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95. The business has a 50 day moving average price of $3.75 and a 200-day moving average price of $3.86. The company has a market cap of $180.61 million, a PE ratio of -1.29 and a beta of 1.93.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, research analysts anticipate that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, major shareholder Group Walters purchased 4,335,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the acquisition, the insider owned 17,844,973 shares of the company's stock, valued at $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.80% of the company's stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Spark Investment Management LLC bought a new position in Zentalis Pharmaceuticals during the second quarter valued at about $61,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $126,000. Stonepine Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $783,678. Seven Fleet Capital Management LP grew its position in shares of Zentalis Pharmaceuticals by 188.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company's stock valued at $1,451,000 after acquiring an additional 207,600 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $5,406,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc NASDAQ: ZNTL is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company's research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis' lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.